Compound useful as toll-like receptor 7 activation inhibitor
AssigneesToyama Prefectural University, Teika Pharmaceutical Co., Ltd., National Institute of Advanced Industrial Science and Technology
InventorsYoshinori Nagai, Naoki Okamoto, Shigeto Fujishita, Takatsugu Hirokawa
Life of this patent
Estimating the term…
Abstract
CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.
Claims10
A chemical compound represented by the following formula
- a pharmacologically acceptable salt thereof, or a prodrug thereof,
- wherein in formulae (I) and (II),
- R1 is:
- C3-5 alkoxy group containing at least two oxygen atoms;
- C2-4 alkoxy group containing at least one hydroxyl group;
- and
- the following formula
- wherein R2 and R3 are each independently C1-3 alkyl group;
- or
- wherein C ring is a 3- to 7-membered nitrogen-containing heterocyclic ring,
- R4 is a group represented by a combination of —NH—, —O—, —CF2—, —CHF—, —C2H2F2— or —CHF—X—CHF—, and
- X is C1-4 alkyl group.
Dependencies are inferred from the claim text.